FF
RVNC

FourThought Financial’s Revance Therapeutics, Inc. RVNC Stock Holding History

FourThought Financial’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$66K Hold
2,453
– – 0.01% 527
2022
Q2 		$34K Buy
2,453
+422
+21% +$6.5K 0.01% 729
2022
Q1 		$40K Buy
2,031
+269
+15% +$4.08K 0.01% 734
2021
Q4 		$29K Sell
1,762
-274
-13% -$4.57K ﹤0.01% 834
2021
Q3 		$56K Buy
2,036
+17
+0.8% +$485 0.01% 657
2021
Q2 		$59K Buy
2,019
+79
+4% +$2.28K 0.01% 656
2021
Q1 		$54K Sell
1,940
-284
-13% -$7.86K 0.01% 672
2020
Q4 		$63K Buy
+2,224
New +$57.6K 0.01% 610

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FourThought Financial's RVNC Position: Q3 2022 in Review

FourThought Financial held its Revance Therapeutics, Inc. (RVNC) position steady in Q3 2022 at 2,453 shares worth $66K. The position accounts for 0.01% of the portfolio, ranked #527.

FourThought Financial first reported a position in RVNC in Q4 2020 and has held it in 8 quarters since. 182 funds tracked by Wall St. Rank hold RVNC as of Q3 2022.

  • FourThought Financial held 2,453 shares of Revance Therapeutics, Inc. worth $66K as of Q3 2022.
  • FourThought Financial left its Revance Therapeutics, Inc. share count unchanged in Q3 2022.
  • Revance Therapeutics, Inc. made up 0.01% of FourThought Financial's portfolio in Q3 2022, its #527 holding.
  • FourThought Financial first reported a position in Revance Therapeutics, Inc. in Q4 2020 and has held it in 8 quarters since.
  • 182 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.